180 Life Sciences EV / EBITDA
Cos'è EV / EBITDA di 180 Life Sciences?
EV / EBITDA di 180 Life Sciences Corp. è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su NASDAQ rispetto a 180 Life Sciences
Cosa fa 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Aziende con ev / ebitda simili a 180 Life Sciences
- Halo Collective ha EV / EBITDA di N/A
- Genetron Ltd ha EV / EBITDA di N/A
- Immunome ha EV / EBITDA di N/A
- CuriosityStream ha EV / EBITDA di N/A
- Cornerstone FS Plc ha EV / EBITDA di N/A
- Yuxing InfoTech Investment ha EV / EBITDA di N/A
- 180 Life Sciences ha EV / EBITDA di N/A
- Anglo African Oil & Gas Plc ha EV / EBITDA di N/A
- North Peak Resources ha EV / EBITDA di N/A
- Casablanca ha EV / EBITDA di N/A
- Predictive Oncology ha EV / EBITDA di N/A
- Theranexus SA ha EV / EBITDA di N/A
- 49 North Resources ha EV / EBITDA di N/A